Recent developments highlight clinical progress in the ADAPT trial for chronic lower back pain, FDA regulatory milestones, and strategic collaborations to advance the company’s regenerative therapy platforms.

• Creative Medical reported positive interim data from the ADAPT trial showing functional and pain improvements in chronic lower back pain patients [N1].
• The company reached a major clinical inflection point with positive interim data from the ADAPT trial and CELZ-201 (Olastrocel) for chronic lower back pain [N2].
• Enrollment for the ADAPT trial for chronic lower back pain was completed in December 2025 [N3].
• The company secured FDA clearance for expanded dosing in its back pain trial in March 2025 [N5].
• Creative Medical expanded its AI collaboration with Greenstone Biosciences to advance the IPSCelz platform in February 2025 [N8].
• The company reported 80% efficacy in a Type 2 diabetes trial for CELZ-201 in February 2025 [N7].
• Mid-term data showed reduced opioid use with the StemSpine procedure in February 2025 [N6].

The company has demonstrated progress in clinical development with positive interim data from the ADAPT trial for chronic lower back pain and other clinical programs showing efficacy signals, such as 80% efficacy in a Type 2 diabetes trial. The FDA has granted Fast Track designation to its lead investigational therapy CELZ-201-DDT, potentially enabling accelerated regulatory interactions. The company’s proprietary cell therapy platforms, including ImmCelz™ and AlloStem™, are supported by strong intellectual property and FDA cleared clinical trials. Collaborations with Greenstone Biosciences to develop iPSC lines and integrate AI for drug discovery and biodefense applications may enhance innovation and pipeline expansion. The company maintains a strong liquidity position with a high current ratio and cash reserves to support ongoing operations and clinical trials [N1][N2][N7][N8][S1][S2].

The company operates in a highly competitive biotechnology industry characterized by rapid technological changes and evolving customer demands, which may render its products obsolete or unmarketable. The company has limited commercial activities outside of stem cell concentration kit sales and has not yet commercialized its ImmCelz™ and AlloCelz™ platforms. Regulatory approvals are required before marketing many of its therapies, posing development and commercialization risks. The company has limited marketing and sales capabilities and may incur substantial expenses to build these functions. Financially, the company reported net losses and limited revenue, indicating ongoing reliance on capital raises. Risks also include potential delays or failures in clinical trials, competition from better-resourced companies, and uncertainties related to global economic and supply chain conditions [S1][S2].

Creative Medical Technology Holdings, Inc. leverages proprietary intellectual property including patents related to stem cell therapies and regenerative medicine, supported by FDA cleared clinical trials and Drug Master Files. The company’s AlloStem™ platform benefits from a proprietary Master Cell Bank and Drug Master File registered with the FDA, enabling scalable and universal recipient cell products with immunomodulatory properties. The company’s collaborations with Greenstone Biosciences to develop human induced pluripotent stem cell lines and AI-driven drug discovery further enhance its technological capabilities. The company’s clinical programs have received regulatory designations such as Fast Track status, which may facilitate accelerated development. However, the company operates in a highly competitive and rapidly evolving biotechnology sector, facing challenges from larger, better-resourced competitors and the need for regulatory approvals before commercialization [S1][S2].

• Regulatory Approval Risk: Many of the company’s therapies require FDA approval before commercialization, which involves lengthy and uncertain regulatory processes.
• Competitive Risk: The company faces competition from larger biotechnology and pharmaceutical companies with greater resources and established marketing and sales operations.
• Commercialization Risk: Limited current commercial activities and marketing capabilities may delay or hinder product adoption and revenue growth.
• Technological Obsolescence: Rapid changes in technology and customer demands may render the company’s products and services obsolete or unmarketable.
• Financial Risk: The company has reported net losses and limited revenue, indicating ongoing need for capital to fund operations and clinical development.

• Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company focused on regenerative therapies in immunotherapy, endocrinology, urology, neurology, and orthopedics [S1].
• The company operates through subsidiaries including Creative Medical Technologies, Inc. (CMT), ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC, with CMT conducting commercial operations primarily through sale of disposable stem cell concentration kits for erectile dysfunction and female sexual dysfunction [S1].
• ImmCelz Inc. and AlloCelz LLC have not commenced commercial activities as of the latest filings [S1].
• The company’s ImmCelz™ platform (CELZ-100) uses a patient’s own immune cells that are reprogrammed outside the body and reinjected, aiming to treat multiple indications with regenerative properties [S1].
• The AlloStem™ (CELZ-201-DDT) program is an allogenic human perinatal tissue derived cell therapy in clinical phase, targeting chronic lower back pain and other immune and endocrine disorders, supported by FDA cleared clinical trials and proprietary cell lines [S1].
• The company has ongoing clinical trials including the ADAPT trial for chronic lower back pain using CELZ-201, with positive interim data and completed enrollment as of December 2025 [N1][N2][N3][S1].
• FDA has granted Fast Track designation to CELZ-201-DDT, facilitating accelerated regulatory interactions [S1].
• The company has collaborations with Greenstone Biosciences Inc. to develop human induced pluripotent stem cell (iPSC) lines and integrate AI for drug discovery and biodefense applications [S1][N8].
• Recent clinical data reported include functional and pain improvements in chronic lower back pain patients in the ADAPT trial, 80% efficacy in a Type 2 diabetes trial for CELZ-201, and reduced opioid use with StemSpine [N1][N6][N7].
• The company’s financial snapshot as of December 31, 2025, shows cash and equivalents of approximately $4.5 million, current assets of about $7.4 million, current liabilities of $0.28 million, resulting in a strong current ratio of 25.97 and cash ratio of 15.82 [S1][report_input.sec_financial_snapshot].
• Revenue for the year ended December 31, 2025, was $6,000 with a net loss of approximately $6.0 million and diluted EPS of -2.52 USD per share [S1][report_input.sec_financial_snapshot].
• The company’s operating segment is managed as a single reportable segment, with consolidated financials reviewed by the CEO [S1].
• The company has raised capital through registered direct offerings and warrant exercises, with proceeds used to fund clinical trials and operations [S1].
• The company’s products and services face risks from rapid technological changes, competition from better-resourced companies, and the need for regulatory approvals before commercialization [S1][S2].
• The company’s marketing and sales capabilities are limited, and it may incur substantial expenses to develop these functions [S2].
• The company recognizes revenue primarily from sales of disposable stem cell concentration kits, with deferred revenue reported as minimal [S2].
• The company’s clinical programs include treatments for Type 1 diabetes, chronic lower back pain, and other immune and endocrine disorders, with multiple FDA clearances and IND approvals [S1].